Read by QxMD icon Read


Nina H Grootendorst-van Mil, Anna R M Huiskens, Sieds Dieleman, Tom K Birkenhäger
The clinical management of patients with treatment-resistant psychotic disorders is still challenging despite years of extensive research. If first-line antipsychotic treatment proves ineffective, clozapine is considered golden standard. Herein, we report on a patient with schizoaffective disorder that initially showed no response to treatment with clozapine and ECT and therefore reached a therapeutic dead end. After an unintentional exposure to supratherapeutic clozapine levels, related to a pneumonia, a significant and persistent reduction of psychotic symptoms occurred...
2018: Case Reports in Psychiatry
Leif Hommers, Magdalena Scharl, Gudrun Hefner, Matthias Hohner, Matthias Fischer, Bruno Pfuhlmann, Jürgen Deckert, Stefan Unterecker
OBJECTIVES: Valproic acid and clozapine are drugs commonly used in the treatment of schizophrenic and schizoaffective disorders. Pharmacokinetic interactions of valproic acid with several drugs are well known, yet results concerning the interaction with clozapine are inconsistent. METHODS: Steady-state dose-corrected serum concentrations of clozapine and its main metabolite norclozapine were retrospectively analyzed in 45 patients receiving both clozapine and valproic acid...
April 3, 2018: Journal of Clinical Psychopharmacology
Amy J Lynham, Leon Hubbard, Katherine E Tansey, Marian L Hamshere, Sophie E Legge, Michael J Owen, Ian R Jones, James T R Walters
BACKGROUND: Cognitive impairments are well-established features of schizophrenia, but there is ongoing debate about the nature and degree of cognitive impairment in patients with schizoaffective disorder and bipolar disorder. We hypothesized that there is a spectrum of increasing impairment from bipolar disorder to schizoaffective disorder bipolar type, to schizoaffective disorder depressive type and schizophrenia. METHODS: We compared performance on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery between participants with schizophrenia ( n = 558), schizoaffective disorder depressive type ( n = 112), schizoaffective disorder type ( n = 76), bipolar disorder ( n = 78) and healthy participants ( n = 103) using analysis of covariance with post hoc comparisons...
April 5, 2018: Journal of Psychiatry & Neuroscience: JPN
Marc Cantillon, Robert Ings, Arul Prakash, Laxminarayan Bhat
BACKGROUND AND OBJECTIVE: RP5063 is a novel multimodal dopamine (D)-serotonin (5-HT) stabilizer possessing partial agonist activity for D2/3/4 and 5-HT1A/2A , antagonist activity for 5-HT2B/2C/7, and moderate affinity for the serotonin transporter. Phase 2 trial data analysis of RP5063 involving patients with schizophrenia and schizoaffective disorder defined: (1) the pharmacokinetic profile; and (2) the pharmacokinetic/pharmacodynamic relationships. METHODS: Pharmacokinetic sample data (175 patients on RP5063; 28 doses/patient) were analyzed, utilized one- and two-compartment models, and evaluated the impact of covariates...
April 4, 2018: European Journal of Drug Metabolism and Pharmacokinetics
Sarah K Brown, Rachel B Nowlin, Rebecca Sartorelli, Johan Smith, Karen Johnson
OBJECTIVE: The aim of the study was to explore patient perception and perceived benefit of electroconvulsive therapy (ECT) by assessing the real-world experience of adult patients who received ECT, focusing on clinical outcomes and patient satisfaction. METHODS: This retrospective study analyzed patient self-report of depressive symptoms (Patient Health Questionnaire), perception of physical and cognitive ECT adverse effects (ECT Outcomes Survey) and satisfaction with treatment (Patient Satisfaction Survey)...
April 2, 2018: Journal of ECT
Hong-Zhen Fan, Jian-Jun Zhu, Jian Wang, Jie-Feng Cui, Nan Chen, Jing Yao, Shu-Ping Tan, Jing-Hui Duan, Hao-Tian Pang, Yi-Zhuang Zou
Short form of the Wechsler Adult Intelligence Scale is often needed to quickly estimate intelligence for time-saving or screening in clinical practice. The present study aims to examine the psychometric properties of Chinese version of the four-subtest index-based short form (SF4) of WAIS-IV (FS) and to confirm its clinical application. 1,757 adults from the WAIS-IV Chinese version standardization sample and 239 mixed clinical samples including patients with schizophrenia or schizoaffective disorder (SCH), obsessive-compulsive disorder (OCD), and mild or moderate intellectual disability (ID) were used...
March 28, 2018: Archives of Clinical Neuropsychology: the Official Journal of the National Academy of Neuropsychologists
T Scott Stroup, Tobias Gerhard, Stephen Crystal, Cecilia Huang, Zhiqiang Tan, Melanie M Wall, Chacku M Mathai, Mark Olfson
OBJECTIVE: The authors examined the use of different classes of psychotropic medication in outpatient treatment of schizophrenia and schizoaffective disorder. METHODS: Data from the United States Medicaid program were used to examine psychotropic medication use in a cohort of patients who had a diagnosis of schizophrenia or schizoaffective disorder in the calendar year 2010. RESULTS: The cohort of Medicaid recipients who filled one or more prescriptions for a psychotropic medication in 2010 included 116,249 patients classified as having schizophrenia and 84,537 classified as having schizoaffective disorder...
April 2, 2018: Psychiatric Services: a Journal of the American Psychiatric Association
Anthony P Morrison, Heather Law, Lucy Carter, Rachel Sellers, Richard Emsley, Melissa Pyle, Paul French, David Shiers, Alison R Yung, Elizabeth K Murphy, Natasha Holden, Ann Steele, Samantha E Bowe, Jasper Palmier-Claus, Victoria Brooks, Rory Byrne, Linda Davies, Peter M Haddad
BACKGROUND: Little evidence is available for head-to-head comparisons of psychosocial interventions and pharmacological interventions in psychosis. We aimed to establish whether a randomised controlled trial of cognitive behavioural therapy (CBT) versus antipsychotic drugs versus a combination of both would be feasible in people with psychosis. METHODS: We did a single-site, single-blind pilot randomised controlled trial in people with psychosis who used services in National Health Service trusts across Greater Manchester, UK...
March 28, 2018: Lancet Psychiatry
Brian P Keane, Lisa N Cruz, Danielle Paterno, Steven M Silverstein
Background: Past studies using the Bonn Scale for the Assessment of Basic Symptoms (hereafter, Bonn Scale) have shown that self-reported perceptual/cognitive disturbances reveal which persons have or will soon develop schizophrenia. Here, we focused specifically on the clinical value of self-reported visual perceptual abnormalities (VPAs) since they are underexplored and have been associated with suicidal ideation, negative symptoms, and objective visual dysfunction. Method: Using the 17 Bonn Scale vision items, we cross-sectionally investigated lifetime occurrence of VPAs in 21 first-episode psychosis and 22 chronic schizophrenia/schizoaffective disorder (SZ/SA) patients...
2018: Frontiers in Psychiatry
Maria Nystazaki, Katerina Pikouli, Eva-Maria Tsapakis, Maria Karanikola, Dimitrios Ploumpidis, Giorgos Alevizopoulos
OBJECTIVE: Providing informed, consent requires patients' Decision-Making Capacity for treatment. We evaluated the Decision Making Capacity of outpatients diagnosed with schizophrenia and schizoaffective disorder on treatment with Long Acting Injectable Antipsychotic medication. METHOD: This is a retrospective, cross-sectional, correlational study conducted at two Depot Clinics in Athens, Greece. Participants included 65 outpatients diagnosed with schizophrenia and schizoaffective disorder on treatment with Long Acting Injectable Antipsychotics...
April 2018: Archives of Psychiatric Nursing
Mary A Jansen
This article presents a short, easy-to-use guideline for clinicians working with people with serious mental illness, particularly those with schizophrenia, schizoaffective disorder, delusional disorders, other psychotic disorders, or depression with significant impact on functioning, and may be of use for those working with individuals with bipolar disorder. This guideline is not meant to supplant the more detailed, excellent clinical practice guidelines that have been developed and published. Rather, the charts and explanation presented here are designed as a step-by-step tool that clinicians can use to ensure they are following the most appropriate course of action and providing the best psychosocial rehabilitation services possible for persons with these disorders...
March 26, 2018: Psychiatry
Adib Essali, Karla Soares-Weiser, Hanna Bergman, Clive E Adams
BACKGROUND: Schizophrenia and related disorders affect a sizable proportion of any population. Antipsychotic medications are the primary treatment for these disorders. Antipsychotic medications are associated with a variety of adverse effects including tardive dyskinesia. Dyskinesia is a disfiguring movement disorder of the orofacial region that can be tardive (having a slow or belated onset). Tardive dyskinesia is difficult to treat, despite experimentation with several treatments. Calcium channel blockers (diltiazem, nifedipine, nimodipine, verapamil, flunarizine) have been among these experimental treatments...
March 26, 2018: Cochrane Database of Systematic Reviews
Tara Kingston, Paul J Scully, David J Browne, Patrizia A Baldwin, Anthony Kinsella, Eadbhard O'Callaghan, Vincent Russell, John L Waddington
OBJECTIVE: While long-term outcome following a first psychotic episode is well studied in schizophrenia (SZ), schizoaffective disorder (SA), and bipolar disorder (BD), major depressive disorder with psychotic features (MDDP) has received less investigation. This study compares MDDP with SZ, SA, and BD at 6-year follow-up. METHODS: At 6 years after a first psychotic episode, follow-up data on psychopathology, functioning, quality of life, and service engagement were obtained for 27 cases of MDDP in comparison to 60 SZ, 27 SA, and 35 BD...
March 25, 2018: CNS Neuroscience & Therapeutics
Elizabeth C Thomas, Jessica Murakami-Brundage, Nina Bertolami, Aaron T Beck, Paul M Grant
A requisite step for testing cognitive theories regarding the role of self-concept in schizophrenia is the development of measures that follow a cognitive conceptualization and better capture the multifaceted nature of this construct. The purpose of this study was to examine the psychometric properties a new self-concept measure, the Beck Self-Esteem Scale-Short Form (BSES-SF), based on a sample of 204 individuals with schizophrenia or schizoaffective disorder. We evaluated the BSES-SF's dimensionality, internal consistency reliability, and construct and divergent validity using confirmatory factor analysis, Cronbach's alpha, Pearson correlations, independent samples t-tests, and one-way analysis of variance...
March 6, 2018: Psychiatry Research
Marlies Onken, Inge Mick, Christof Schaefer
Schizophrenic or schizoaffective disorders often occur in early adulthood and thus affect women of childbearing age. For paliperidone information about reproductive safety is wanting. Therefore, we evaluated data from the German Embryotox pharmacovigilance institute regarding paliperidone therapy during pregnancy. The German Embryotox pharmacovigilance institute offers risk assessment on drug use in pregnancy and documents the outcome of more than 3500 drug-exposed pregnancies per year. In our study, we analyze the outcome of all pregnancies with paliperidone exposure, which have been assessed by our institute between January 2007 and June 2016...
March 22, 2018: Archives of Women's Mental Health
Graham M L Eglit, Barton W Palmer, A'verria S Martin, Xin Tu, Dilip V Jeste
Loneliness is a highly prevalent experience in schizophrenia. Theoretical models developed in the general population propose that loneliness is tantamount to a feeling of being unsafe, is accompanied by enhanced environmental threat perception, and leads to poor physical, emotional, and cognitive functioning. Previous research has reported that loneliness is associated with poorer physical and emotional health in schizophrenia; however, few studies have directly compared loneliness and its correlates in persons with schizophrenia and non-psychiatric comparison subjects...
2018: PloS One
H-J Assion, A Schweppe, H Reinbold, U Frommberger
BACKGROUND: Bipolar disorder and schizophrenia are severe mental illnesses, each with a prevalence of approximately 1-2% in the general population. There is considerable controversy about differentiating schizophrenia from schizoaffective or bipolar disorder owing to many similarities in psychopathology, progression, and biological factors. The aim of this study was to identify similarities and differences in the pharmacological treatment of these disorders by comparing the prescription patterns...
March 21, 2018: Der Nervenarzt
Moritz E Wigand, Fabian U Lang, Annabel S Müller-Stierlin, Lea Reichhardt, Silvana Trif, Thomas G Schulze, Werner Strik, Thomas Becker, Markus Jäger
BACKGROUND: A neurobiologically informed, system-specific psychopathological approach has been suggested for use in schizophrenia. However, to our knowledge, such an approach has not been used to prospectively describe the course of schizophrenia. SAMPLING AND METHODS: We assessed psychopathology in a well-described sample of 100 patients with schizophrenia or schizoaffective disorder with the Bern Psychopathology Scale (BPS) at 6-month intervals for up to 18 months...
March 14, 2018: Psychopathology
Yuanhan Bai, Xi Yang, Zhiqiang Zeng, Haichen Yang
BACKGROUND: Ritualistic behaviors are common in obsessive compulsive disorder (OCD), while catatonic stupor occasionally occurs in psychotic or mood disorders. Schizoaffective disorder is a specific mental disorder involving both psychotic and affective symptoms. The syndrome usually represents a specific diagnosis, as in the case of the 10th edition of the International Classification of Diseases (ICD-10) or the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)...
March 13, 2018: BMC Psychiatry
Matthew W Roché, Douglas J Boyle, Chia-Cherng Cheng, Jill Del Pozzo, Lindsay Cherneski, Joe Pascarella, Alicia Lukachko, Steven M Silverstein
Research has consistently demonstrated that people diagnosed with serious mental illness (SMI) are at increased risk for violent ideation and behavior (VIB) and that this is especially the case for SMI patients with comorbid substance use disorders (SUD). Despite this, what is still largely unknown is the relative prevalence of VIB across diagnostic categories, whether the rates of VIB in SMI groups exceed the rates observed in people with SUD only, and which demographic factors increase the likelihood of VIB under different circumstances for people with SMI...
March 1, 2018: Journal of Interpersonal Violence
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"